SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will discuss the Company’s recent progress and upcoming sales expectations on Tuesday, December 4, 2018 at 4:00 pm ET (3:00 pm CT) in a Lytham Partners’ Virtual Investors Conference Presentation. The presentation will be available online with interested parties able to participate by following the webcast links below at the time of the presentation.

The presentation will be conducted by Mr. Dwight Egan, Chairman and Chief Executive Officer of the Company, and is expected to consist of a Company progress update and review of milestones reached in 2018, followed by the Company’s expectations for near-term sales and questions from the audience. The event will be moderated by Joe Diaz, managing partner at Lytham Partners.

A replay of the presentation will be available on demand following the conclusion of the live event.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with a patented diagnostic testing technology and development platform that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Company Contact:
Andrew Benson
Co-Diagnostics Investor Relations
801-438-1036
investors@codiagnostics.com

Investor Contact:
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
602-889-9700
codx@lythampartners.com